UK-PBC National Audit: a collaborative success in identifying critical shortfalls

Notably, disparities were found in the optimal dosing of ursodeoxycholic acid (UDCA), risk stratification using UDCA response, assessment of clinical symptoms (pruritus and fatigue), bone density assessment and in the referral of high-risk patients for consideration of liver transplant. In response to these findings, a steering committee was formed and in collaboration with the BSG, British Association for Study of the Liver (BASL) and the PBC foundation, the national ‘UK-PBC Audit’ was launched. The full audit outcomes will be presented at the 2022 BASL Annual Meeting and the 2022 European Association for the Study of the Liver International Liver Congress.